Levosemotiadil Fumarate

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameLevosemotiadil Fumarate
Drug Alias Namelevosemotiadilum富马酸左司莫地尔左司莫地尔富马酸盐SA-3212SD-3212
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPotassium channel blockersSodium channel alpha subunit blockersVoltage-gated calcium channel blockers +[4] 
TargetsPotassium channelSodium channel alpha subunitVoltage-gated calcium channel +[4] 
Therapy Area/IndicationsArrhythmias, Cardiac
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesSanten Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAstellas Pharma IncSanten
Active IndicationsN/A
Inactive IndicationsArrhythmias, Cardiac

Other Information

ATC CodeN/A
Related LinksKEGG